Hospital de Clinicas de Porto Alegre
hcpa.edu.brLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
444
Active
46
Phase 3
50
Total enrollment
218,926
Pipeline matrix
Showing 29 of 29 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Early Caffeine administration | — | — | — | — | — | 1 | |
| Cefuroxime | — | — | — | — | — | 1 | |
| Cefuroxime Axetil | — | — | — | — | — | 1 | |
| Desmopressin | — | — | — | — | — | 1 | |
| Sodium Chloride | — | — | — | — | — | 1 | |
| Immediate-release Methylphenidate | — | — | — | — | — | 1 | |
| Letrozole | — | — | — | — | — | 1 | |
| Methotrexate Sodium | — | — | — | — | — | 1 | |
| Discontinuation of MRAs | — | — | — | — | — | 1 | |
| Continue MRAs | — | — | — | — | — | 1 | |
| Marrow-derived mesenchymal stromal cell | — | — | — | — | — | 1 | |
| Iron Carboxymaltose | — | — | — | — | — | 1 | |
| Dapagliflozin 10mg Tab | — | — | — | — | — | 1 | |
| Furosemide 40 Milligrams. | — | — | — | — | — | 1 | |
| Hydrochlorothiazide (HCTZ) 25 milligrams. | — | — | — | — | — | 1 | |
| Acetazolamide 250 milligrams. | — | — | — | — | — | 1 | |
| Dapagliflozin | — | — | — | — | — | 1 | |
| Potassium Chloride Oral Product | — | — | — | — | — | 1 | |
| Povidone-iodine | — | — | — | — | — | 1 | |
| Saline solution | — | — | — | — | 2 | ||
| Active comparator Taurine | — | — | — | — | — | 1 | |
| NK cell | — | — | — | — | — | 1 | |
| Tacrolimus modified-release | — | — | — | — | — | 1 | |
| tacrolimus ointment 0.1% | — | — | — | — | — | 1 | |
| Tocilizumab | — | — | — | — | — | 1 | |
| Normal Saline | — | — | — | — | — | 1 | |
| Transcranial Photobiomodulation | — | — | — | — | — | 1 | |
| Duloxetine (60 mg) once daily | — | — | — | — | — | 1 | |
| Duloxetine 60 mg | — | — | — | — | — | 1 |
Next readouts
- 2020-08-17
- 2025-10
- 2025-12-31
- 2026-05-24
- 2026-06
- 2026-12
- 2026-12-31
- 2027-07
- 2027-08-31
- 2027-12
Top conditions
- Hypertension24
- Fibromyalgia13
- Obesity12
- Heart Failure12
- Diabetes Mellitus, Type 211
- Pain9
- Chronic Pain7
- Diabetes Mellitus6
Frequently asked questions about Hospital de Clinicas de Porto Alegre
- How many clinical trials does Hospital de Clinicas de Porto Alegre have on ClinicalTrials.gov?
- Hospital de Clinicas de Porto Alegre is listed as the lead sponsor on 444 clinical trials in ClinicalTrials.gov, 46 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Hospital de Clinicas de Porto Alegre's trials are in Phase 3?
- 50 of Hospital de Clinicas de Porto Alegre's trials are in Phase 3, spread across 29 active drug programs.
- What therapeutic areas does Hospital de Clinicas de Porto Alegre focus on?
- Hospital de Clinicas de Porto Alegre's most-studied conditions on ClinicalTrials.gov are Hypertension, Fibromyalgia, Obesity, Heart Failure, Diabetes Mellitus, Type 2.
- When are Hospital de Clinicas de Porto Alegre's next clinical trial readouts?
- Hospital de Clinicas de Porto Alegre has 10 upcoming primary-completion readouts tracked here; the soonest is “Cell Therapy Associated With Endobronchial Valve”, expected around 2020-08-17.